• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Development of influenza A(H7N9) candidate vaccine viruses with improved hemagglutinin antigen yield in eggs

tetano

Editor, Senior Moderator
Influenza Other Respir Viruses. 2015 May 11. doi: 10.1111/irv.12322. [Epub ahead of print]
[h=1]Development of influenza A(H7N9) candidate vaccine viruses with improved hemagglutinin antigen yield in eggs.[/h] Ridenour C[SUP]1[/SUP], Johnson A[SUP]1[/SUP], Winne E[SUP]2[/SUP], Hossain J[SUP]1[/SUP], Mateu-Petit G[SUP]1[/SUP], Balish A[SUP]1[/SUP], Santana W[SUP]2[/SUP], Kim T[SUP]1[/SUP], Davis C[SUP]1[/SUP], Cox NJ[SUP]1[/SUP], Barr JR[SUP]2[/SUP], Donis RO[SUP]1[/SUP], Villanueva J[SUP]1[/SUP], Williams TL[SUP]2[/SUP], Chen LM[SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] The emergence of avian influenza A(H7N9) virus in poultry causing zoonotic human infections was reported on March 31, 2013. Development of A(H7N9) candidate vaccine viruses (CVV) for pandemic preparedness purposes was initiated without delay. Candidate vaccine viruses were derived by reverse genetics using the internal genes of A/Puerto/Rico/8/34 (PR8). The resulting A(H7N9) CVVs needed improvement because they had titers and antigen yields that were suboptimal for vaccine manufacturing in eggs, especially in a pandemic situation.
[h=4]METHODS:[/h] Two CVVs derived by reverse genetics were serially passaged in embryonated eggs to improve the hemagglutinin (HA) antigen yield. The total viral protein and HA antigen yields of six egg-passaged CVVs were determined by the BCA assay and isotope dilution mass spectrometry (IDMS) analysis, respectively. CVVs were antigenically characterized by hemagglutination inhibition (HI) assays with ferret antisera.
[h=4]RESULTS:[/h] Improvement of total viral protein yield was observed for the six egg-passaged CVVs; HA quantification by IDMS indicated approximately a two-fold increase in yield of several egg-passaged viruses as compared to that of the parental CVV. Several different amino acid substitutions were identified in the HA of all viruses after serial passage; however HI tests indicated that the antigenic properties of two CVVs remained unchanged.
[h=4]CONCLUSIONS:[/h] If influenza A(H7N9) viruses were to acquire sustained human to human transmissibility, the improved HA yield of the egg-passaged CVVs generated in this study could expedite vaccine manufacturing for pandemic mitigation. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.


[h=4]KEYWORDS:[/h] Antigen Yield; H7N9; Hemagglutinin; Influenza; Serial passage; Vaccine

PMID: 25962412 [PubMed - as supplied by publisher]
 
Back
Top Bottom